We are live on
!
Find out more
HS
HighVista Strategies Portfolio holdings
AUM
$362M
1-Year Est. Return
230.96%
This Fund
S&P 500
This Quarter
Est. Return
+5.82%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$123M
AUM Growth
-$45.7M
(-27%)
Cap. Flow
-$44.3M
Cap. Flow
% of AUM
-36.11%
Top 10 Holdings %
Top 10 Hldgs %
29.13%
Holding
142
New
37
Increased
19
Reduced
19
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$3.21M |
| 2 |
Albertsons Companies
ACI
|
+$3.18M |
| 3 |
OSH
Oak Street Health, Inc.
OSH
|
+$2.89M |
| 4 |
Immunovant
IMVT
|
+$2.84M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$2.49M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dell
DELL
|
+$14.3M |
| 2 |
Mastercard
MA
|
+$12.9M |
| 3 |
FISV
Fiserv Inc
FISV
|
+$8.83M |
| 4 |
Visa
V
|
+$8.72M |
| 5 |
MSDAU
MSD Acquisition Corp. Unit
MSDAU
|
+$5.05M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 67.14% |
| 2 | Technology | 10.92% |
| 3 | Consumer Discretionary | 4.92% |
| 4 | Financials | 4.39% |
| 5 | Communication Services | 4.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Incyte
INCY
$24.5B
| $786K | 0.64% |
10,879
| – | – |
|
52
Crinetics Pharmaceuticals
CRNX
$8.95B
| $775K | 0.63% |
48,245
-45,648
| -49% | -$845K |
|
53
Biogen
BIIB
$30.1B
| $763K | 0.62% |
2,743
| – | – |
|
54
Kymera Therapeutics
KYMR
$9.11B
| $756K | 0.62% |
+25,530
| New | +$823K |
|
|
55
Visa
V
$677B
| $753K | 0.61% |
3,340
-39,175
| -92% | -$8.72M |
|
|
AMRN
56
Amarin Corp
AMRN
$296M
| $751K | 0.61% |
25,034
| – | – |
|
57
Vaxcyte
PCVX
$8.81B
| $735K | 0.6% |
19,606
| – | – |
|
58
United Therapeutics
UTHR
$22.1B
| $718K | 0.58% |
3,204
| – | – |
|
|
AKRO
59
DELISTED
Akero Therapeutics
AKRO
| $713K | 0.58% |
18,629
| – | – |
|
60
Prothena Corp
PRTA
$473M
| $706K | 0.58% |
14,572
| – | – |
|
|
ALPN
61
DELISTED
Alpine Immune Sciences Inc
ALPN
| $697K | 0.57% |
+90,287
| New | +$719K |
|
62
Amazon
AMZN
$2.94T
| $679K | 0.55% |
6,570
+1,370
| +26% | +$132K |
|
63
Madrigal Pharmaceuticals
MDGL
$12.4B
| $677K | 0.55% |
+2,796
| New | +$762K |
|
64
Immunocore
IMCR
$1.74B
| $652K | 0.53% |
13,194
| – | – |
|
|
FISV
65
Fiserv Inc
FISV
$28B
| $642K | 0.52% |
5,682
-80,244
| -93% | -$8.83M |
|
66
Rhythm Pharmaceuticals
RYTM
$7.77B
| $633K | 0.52% |
35,478
| – | – |
|
|
67
Mastercard
MA
$492B
| $607K | 0.49% |
1,670
-35,524
| -96% | -$12.9M |
|
|
MRTX
68
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $585K | 0.48% |
15,738
+4,035
| +34% | +$181K |
|
69
AnaptysBio
ANAB
$1.71B
| $549K | 0.45% |
25,219
+11,215
| +80% | +$273K |
|
70
Intuit
INTU
$92B
| $544K | 0.44% |
1,220
+600
| +97% | +$246K |
|
71
Syndax Pharmaceuticals
SNDX
$1.81B
| $541K | 0.44% |
25,604
+6,943
| +37% | +$173K |
|
72
Arvinas
ARVN
$588M
| $524K | 0.43% |
19,197
+3,203
| +20% | +$101K |
|
|
BLU
73
DELISTED
BELLUS Health Inc.
BLU
| $492K | 0.4% |
68,292
-23,201
| -25% | -$180K |
|
|
EDR
74
DELISTED
Endeavor Group Holdings, Inc.
EDR
| $458K | 0.37% |
+19,160
| New | +$427K |
|
|
SWTX
75
DELISTED
SpringWorks Therapeutics
SWTX
| $454K | 0.37% |
17,647
-17,156
| -49% | -$501K |
|
Similar funds
SIAG
MS
WTFG
A6
PI
ACM
PPG
PWC
HighVista Strategies's Q1 2023 Portfolio in Review
As of Q1 2023, HighVista Strategies held 142 positions worth $123M, down 27% from $168M the previous quarter. Its ten largest holdings account for 29% of the portfolio.
HighVista Strategies withdrew a net $44.3M in Q1 2023, closing 34 positions and reducing 19 holdings. Its most notable exit was Dell, an estimated $14.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 47% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, HighVista Strategies opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $3.17M.
- HighVista Strategies's largest Q1 2023 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 29,000 shares worth $3.17M.
- HighVista Strategies added most to Seagen Inc. Common Stock in Q1 2023, an estimated $2.49M increase.
- HighVista Strategies's biggest Q1 2023 reduction was Mastercard, cutting an estimated $12.9M.
- HighVista Strategies fully exited Dell in Q1 2023, selling an estimated $14.3M.
- HighVista Strategies's ten largest holdings make up 29% of its $123M portfolio in Q1 2023.
- HighVista Strategies opened 37 new positions and closed 34 in Q1 2023.
- HighVista Strategies's portfolio value fell 27% quarter-over-quarter to $123M.
Based on HighVista Strategies's 13F filing for Q1 2023, filed 15 May 2023.